Navigation Links
Life Technologies to Launch Ion 318 Chip in Second Half of 2011 with 1Gb of Data Output
Date:2/23/2011

CARLSBAD, Calif., Feb. 23, 2011 /PRNewswire/ -- Life Technologies Corporation (Nasdaq: LIFE) today announced that the Ion 318 semiconductor sequencing chip will be available for early access in September of this year, complete with RNA-Seq kits and analysis software, providing up to 1Gb of data output – 100 times more than the original Ion 314 chip introduced two months ago with the Ion Personal Genome Machine (PGM™) sequencer.

(Logo:  http://photos.prnewswire.com/prnh/20110216/MM49339LOGO)

"Ion Torrent has increased the number of accessible sensors on the Ion 318 chip to 11 million, from 1.2 million on the Ion 314 chip and 6.1 million on the Ion 316 chip," said Gregg Fergus, President of Ion Torrent.  "The Ion 318 is ideal for applications like transcriptome sequencing, miRNA sequencing and ChIP-Seq.  The Ion 318 requires no changes or upgrades to the Ion PGM sequencer – with Ion Torrent 'The Chip is the Machine,' so sequencing is easier and more economical than ever before."

ScalabilityInternally, Ion Torrent has already achieved read lengths in excess of 300bp and improvements in chemistry and loading are expected to increase chip utilization by five-fold.  By combining additional reads with longer read lengths, the company will achieve exceptional scalability on its Ion PGM sequencing platform and expects to reach read lengths of up to 400bp in 2012.

SimplicityAs with the Ion 314 and Ion 316 chips, the Ion 318 chip will use simple PostLight™ sequencing chemistry, which requires no modified nucleotides, fluorescence, chemiluminescence or enzymatic cascades.  As a result, Life Technologies will continue to deliver low-cost reagents and low-cost detection.  The Ion 318 will also leverage four decades of exponential improvement in semiconductor technology, also known as Moore's Law.  This enables the Ion 318 to be priced the same as the Ion 316, even while delivering a 50-fold reduction in sequencing cost – less than a year after the Ion 314 launch.  

SpeedBecause of its simple and flexible workflow, the Ion PGM enables parallel processing of 8 samples per operator, which allows researchers to go from sample to result in less than one day, making it the fastest long read sequencers on the market.  Ion 318 chips will continue to offer incredible sequencing speeds, while delivering up to 1Gb of highly accurate sequence.

The Ion Personal Genome Machine sequencer is for research use only.  Not for use in diagnostic procedures.

About Life TechnologiesLife Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company dedicated to improving the human condition.  Our systems, consumables and services enable researchers to accelerate scientific and medical advancements that make life even better.  Life Technologies customers do their work across the biological spectrum, working to advance the fields of discovery and translational research, molecular medicine, stem cell-based therapies, food safety and animal health, and 21st century forensics.  The company manufactures both molecular diagnostic and research use only products.  Life Technologies' industry-leading brands are found in nearly every life sciences lab in the world and include innovative instrument systems under the Applied Biosystems and Ion Torrent names, as well as, the broadest range of reagents with its Invitrogen, Gibco, Ambion, Molecular Probes and Taqman products.  Life Technologies had sales of $3.6 billion in 2010, has a workforce of approximately 11,000 people, has a presence in approximately 160 countries, and possesses one of the largest intellectual property estates in the life sciences industry, with approximately 3,900 patents and exclusive licenses.  For more information on how we are making a difference, please visit our website: http://www.lifetechnologies.com.  Follow Life Technologies on Twitter @LIFECorporation and on Facebook.

Life Technologies' Safe Harbor StatementThis press release includes forward-looking statements about Life Technologies' anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.Ion Torrent ContactWes Conard650-243-6019wes.conard@lifetech.com
'/>"/>

SOURCE Life Technologies Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
2. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
3. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
4. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
5. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
6. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
7. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
8. Senesco Technologies Initiates Preclinical Studies for Cancer Target
9. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
10. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
11. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 Research ... Pharmacogenomics Market Size, Market Share, Application Analysis, Regional Outlook, Growth ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 ... Mn by 2024, expanding at a CAGR of 5.6% from ...
(Date:4/20/2017)... -- Research and Markets has announced the addition ... Analysis By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, ... report to their offering. ... The Latin American pharmaceutical contract manufacturing services market is ... Low drug registration cost in Latin American countries and continuous ...
(Date:4/19/2017)... , April 19, 2017 The Mobile X-Ray product ... a healthy CAGR during the forecast period Mobile ... the global digital mobile X-Ray devices market, which is estimated ... 2017, expanding at a CAGR of 7% over the forecast ... opportunity of more than US$ 100 Mn in 2017 over ...
Breaking Medicine Technology:
(Date:4/21/2017)... , ... April 21, 2017 , ... ... weeklong campaign, AWARE: A Week of Addiction and Recovery Education, from April 24 ... treating and preventing substance use disorders. , The mission of AWARE is ...
(Date:4/21/2017)... ... April 21, 2017 , ... Northern California Medical Associates ... Spring Symposium on April 1, 2017 in Santa Rosa. This well-attended annual conference ... providers an opportunity to learn about cutting edge treatments, to collaborate, share research ...
(Date:4/21/2017)... ... April 21, 2017 , ... Providing for loved ones before one’s passing is ... where to even begin. “Now more than ever there are some questions that are ... and your family,” said attorney Lisa Edgar Dickman, founder of the Law Offices of ...
(Date:4/21/2017)... , ... April 21, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... leaders in hopes of squashing a global crisis with solution to peace plan. Yisrayl says ... work because the plan is given by the Creator Himself. , Yisrayl says war ...
(Date:4/21/2017)... Texas (PRWEB) , ... April 21, 2017 , ... ... sound familiar? These are five common elements between the Obamacare program that ... hog control program which uses Warfarin poison to kill hogs. , Like ...
Breaking Medicine News(10 mins):